Compound Overview
What Is AICAR?
AICAR — formally 5-Aminoimidazole-4-carboxamide ribonucleotide — is a nucleoside analog also referred to as acadesine. It is not a peptide. Rather, AICAR is a naturally occurring purine nucleotide synthesis intermediate that has been used extensively as a reference compound in intracellular signaling research.
In cell models, AICAR is taken up and phosphorylated intracellularly to form ZMP (AICAR-monophosphate). ZMP structurally mimics AMP and has been studied as a means of modulating the AMP:ATP ratio signal recognized by AMP-activated protein kinase (AMPK) — a central node in cellular energy sensing research.
This mechanism makes AICAR (acadesine) one of the most commonly cited tool compounds in published AMPK pathway research conducted in cell culture and preclinical animal models. Its role in purine synthesis pathway research and mitochondrial biogenesis research in preclinical settings has been documented extensively in the literature.
| Common Name | AICAR / Acadesine |
| Full Name | 5-Aminoimidazole-4-carboxamide ribonucleotide |
| Also Known As | AICA Ribonucleoside; Acadesine; ZMP precursor |
| Compound Class | Nucleoside analog / Purine synthesis intermediate |
| Molecular Formula | C9H14N4O7 (nucleoside / acadesine form) |
| Mol. Formula (5'-MP) | C9H14N4O8P (monophosphate form) |
| Molecular Weight | ~338 Da (acadesine, nucleoside form) |
| CAS Number | 2627-69-2 |
| Intracellular Conversion | → ZMP (AICAR-5'-monophosphate) |
| Research Target | AMPK pathway, AMP:ATP sensing |
| SL Vial Size | 50mg |
| Use Classification | For research use only. Not for human use. |
Research Background
Published Research Areas
Published research has examined AICAR (acadesine) across several interconnected cellular and molecular biology domains. The following areas represent the primary research contexts documented in peer-reviewed literature. All research contexts described reflect in vitro and preclinical animal model findings only.
AMPK Research Tool Comparison
AICAR vs. MOTS-c: Two AMPK Pathway Research Tools
Both AICAR and MOTS-c have been studied as AMPK pathway research tools in published literature, but through distinct mechanisms and compound classes.
- Synthetic nucleoside analog — purine synthesis intermediate
- Exogenous compound introduced to research systems
- Converted intracellularly to ZMP, which activates AMPK via AMP:ATP mimicry
- Widely used as reference/positive-control compound in AMPK pathway assays
- Not a peptide — nucleoside/nucleotide class compound
- CAS: 2627-69-2 · MW: ~338 Da
- Endogenous mitochondria-derived peptide — encoded in the 12S rRNA gene
- Naturally produced in mammalian cells under metabolic stress
- Studied for AMPK pathway engagement through distinct upstream signaling pathways
- Peptide compound — amino acid sequence: MRWQEMGYIFYPRKLR
- Published research has examined its role in mitochondrial–nuclear retrograde signaling
- Research pages: MOTS-c Research →
Sequence Labs Supply
AICAR — 50mg Research Vial
Sequence Labs supplies AICAR (acadesine) as a lyophilized research sample, HPLC and mass spectrometry tested by Krause Analytical, with certificate of analysis available through the Finnrick Pulse portal.
- Vial Size 50mg lyophilized
- Form Lyophilized powder
- Purity Standard ≥98% verified
- Testing Method HPLC + Mass Spectrometry
- Testing Lab Krause Analytical
- COA Platform Finnrick Pulse
- Catalog Review Sabrina Runbeck, PA-C
- Compound Class Nucleoside analog (not a peptide)
- Use Classification Research use only · Not for human use
Reconstitution Reference
Introducing Solvent to the Research Sample
The following reference information is provided for qualified laboratory researchers. For research use only. All reconstitution procedures should be performed in accordance with the receiving laboratory's established protocols and safety standards.
Common Questions
AICAR Research FAQ
Continue Your Research
Browse the full Sequence Labs research compound catalog, explore the MOTS-c comparison, or contact us to inquire about AICAR availability and COA access.